The Ordesa Foundation collaborates with Doctors Without Borders to improve the nutrition of Congolese children Blog Post

The Ordesa Foundation will finance 34,000 units of prepared therapeutic food (RUTF) that Doctors Without Borders (MSF) will distribute to children suffering from severe acute malnutrition in the Democratic Republic of Congo. The partnership is part of the work conducted by the Ordesa Foundation to provide funding and advocacy, through direct aid, to projects aimed at children without resources. Since 2007, the Ordesa Group has R&D&i center at Barcelona Science Park (PCB), from which it is actively involved in clinical studies and national and international programs to improve people´s health and quality of life, especially in maternal and infant stage.

 

AWS Truepower takes part in the WindPower American Wind Energy Association fair Blog Post

One more time, AWS Truepower, one of the world’s leading consultancy firms in the field of renewables energies, is present at the Windpower fair of the American Wind Energy Association (AWEA) that is starting today and will run until Thursday at the Orange County Convention Center in Orlando (Florida). The subsidiary company for Europe and Latin America –AWS Truepower SLU– is based at the Parc Cientific de Barcelona (PCB).

Genetic “editing” a new tool to fight inherited disease Blog Post

Researchers at the Hospital Clínic, IDIBAPS, the Hospital Sant Joan de Deu and the Institute for Bioengineering of Catalonia (IBEC) have participated in a study, led by Dr. Juan Carlos Izpisúa Belmonte of the Gene Expression Laboratory at California’s Salk Institute, that uses molecular scissors to remove mitochondrial mutations in mouse eggs. In the study, published today in the journal Cell (doi: 10.1016/j.cell.2015.03.051), researchers developed a simple technique to eliminate mitochondrial mutations in eggs or embryos at an early stage of development.

The Human Protein Atlas will pave the way to personalized medicine Blog Post

World leaders in proteomics are meeting with local doctors and researchers today and tomorrow at CosmoCaixa Barcelona, in an event held by B·Debate, an initiative by Biocat and Obra Social ‘la Caixa’, co-organized in this edition by the Barcelona Science Park (PCB), ProteoRed-ISCIII, Bellvitge Biomedical Research Institute (IDIBELL), Centre for Genomic Regulation (CRG) and Vall d’Hebron Institute of Oncology (VHIO). Four scientists of renowned prestige in this field –including Dr. Eliandre de Oliveira, head of the PCB’s Proteomics Platform– lead this debate.

 

Omega-3 fatty acids stimulate brown adipose tissue metabolism Blog Post

Omega-3 fatty acids are able to stimulate the activation of brown and beige adipose tissues, a discovery that would promote the development of new therapies for obesity and other metabolism diseases, according to a research study published in the journal Nature Communications under the supervision of Professor Francesc Villarroya, from the Department of Biochemistry and Molecular Biomedicine and member of the Institute of Biomedicine of the University of Barcelona (IBUB) –located at PCB– and the Biomedical Research Center Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN) of the Institute of Health Carlos III.

 

Atrian Bakers’s bread Tritordeum, made with the new cereal Agrasys, nominated to the Carrefour Innovation Awards Blog Post

A new type of bread  produced by Atrian Bakers  and made with Tritordeum,  has been nominated for the 2015 Carrefour Innovation Awards. The new type of bread will be subjected to population vote until the 21st of June. Tritordeum cereal is the first man-made cereal without genetic modification suitable for human consumption. Developed in the late 70s by a group of scientists from the Institute for Sustainable Agriculture (IAS) of the Higher Council for Scientific Research (CSIC)), and after 30 years of research, Agrasys -a spin-off company based at the Barcelona Science Park, founded by researchers from the IAS and the industry, launched the new bread to the market in April 2013.

Ordesa saw turnover grow to €112.4 millions, up 4.7%, in 2014 Blog Post

Laboratorios Ordesa today announced its results for the 2014 year, which reveal a growing trend mainly due to increased sales, cutting structural costs, implementing more efficient sales policies and consolidating foreign markets the company had opened in previous years. Since 2007, the Ordesa Group has a R&D&i center at Barcelona Science Park, from where the company actively participates in clinical studies and national and international research projects in the areas of immunology and cognitive development. The elaboration of hydrolyzed cereals, liquid milk, or the launching of the first porridge with bifidus effect, and supplemented infant formulas are some of the results from these projects.